An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.
Kurtz CB, Millet YA, Puurunen MK, Perreault M, Charbonneau MR, Isabella VM, Kotula JW, Antipov E, Dagon Y, Denney WS, Wagner DA, West KA, Degar AJ, Brennan AM, Miller PF.
Kurtz CB, et al. Among authors: kotula jw.
Sci Transl Med. 2019 Jan 16;11(475):eaau7975. doi: 10.1126/scitranslmed.aau7975.
Sci Transl Med. 2019.
PMID: 30651324
Clinical Trial.